Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6UX46
UPID:
ALKL2_HUMAN
Alternative names:
Augmentor alpha
Alternative UPACC:
Q6UX46; B5MC76
Background:
ALK and LTK ligand 2, also known as Augmentor alpha, is a pivotal cytokine that binds to receptor tyrosine kinases LTK and ALK, triggering their activation. This process is crucial for various physiological responses, including neural development and energy regulation. The interaction with LTK is direct, whereas ALK activation also requires heparin-binding, showcasing a nuanced mechanism of action.
Therapeutic significance:
Understanding the role of ALK and LTK ligand 2 could open doors to potential therapeutic strategies. Its involvement in neural development and energy expenditure regulation highlights its potential as a target for therapeutic intervention in related disorders.